T1	intervention 29 55	vascular access strategies
T2	eligibility 531 623	Patients receiving trastuzumab-based neo/adjuvant chemotherapy for early-stage breast cancer
T3	outcome-Measure 669 680	Feasibility
T4	outcome-Measure 910 1029	ates of line-associated complications such as thrombotic events requiring anticoagulation, line infections or phlebitis
T5	outcome 1333 1361	line-associated complication
T8	iv-bin-percent 1274 1279	17.2%
T9	iv-bin-abs 1281 1282	5
T10	intervention-participants 1283 1285	29
T11	cv-bin-abs 1291 1296	14.8%
T12	cv-bin-abs 1298 1299	4
T13	control-participants 1300 1302	27
T14	total-participants 1139 1141	59
T15	total-participants 1163 1165	56
T16	intervention-participants 1199 1201	29
T17	control-participants 1238 1240	27
T7	control 263 310	totally implanted vascular access device (PORT)
